MedTrace Logo

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

NCT02454530 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1160

Last updated 2019-06-28

Study results available
· View outcomes & findings →

Summary

The aim of this study is to describe in real-life conditions the determinants of use of GCSF (Granulocyte Colony-Stimulating Factor) Nivestim® in primary or secondary prophylaxis and in patients receiving chemotherapy for solid tumour according to the chemotherapy context: adjuvant or metastatic setting.

Conditions

  • Chemotherapy-Induced Neutropenia

Interventions

BIOLOGICAL

Nivestim®

Sponsors & Collaborators

  • Hospira, now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-10-18
Completion
2017-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02454530 on ClinicalTrials.gov